Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AbD Serotec, the research and diagnostic antibodies unit of MorphoSys, has entered into a license agreement with The Institute of Cancer Research (ICR), London, which provides AbD Serotec with worldwide exclusive rights to commercialise the prototypic and BrdU antibody clone for research applications.
Subscribe to our email newsletter
Bromodeoxyuridine (BrdU) – an analog of the DNA base thymidine – is a reagent commonly used in the detection of proliferating cells in living tissues and tissue samples.
The agreement covers clone BU1/75 (also known as ICR1), allowing development in a range of formats suitable for various applications such as ELISA, flow cytometry and immunohistochemistry.
AbD Serotec head Dieter Feger said that with this agreement AbD Serotec will become the sole supplier of this important BrdU antibody, a powerful tool to detect cell proliferation and cell kinetics assays.
"This product complements our comprehensive range of high quality cell biology reagents covering key research areas such as apoptosis, cancer, cell signaling, and cell morphology," Feger said.